GG
AUPH icon

Gofen & Glossberg’s Aurinia Pharmaceuticals AUPH Stock Holding History

Gofen & Glossberg’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,500
Closed -$210K – 627
2021
Q3 		$210K Buy
+9,500
New +$151K ﹤0.01% 545

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.05B AUM 111.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Gofen & Glossberg's AUPH Position: Q4 2021 in Review

Gofen & Glossberg sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 9,500 shares — an estimated $210K sold.

Gofen & Glossberg first reported a position in AUPH in Q3 2021 and held it in 1 quarter. The position peaked at $210K in Q3 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

  • Gofen & Glossberg reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Gofen & Glossberg sold 9,500 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $210K.
  • Gofen & Glossberg first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Gofen & Glossberg's Aurinia Pharmaceuticals position peaked at $210K in Q3 2021.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on Gofen & Glossberg's 13F filing for Q4 2021, filed 25 Jan 2022.